{"filing":{"accession_number":"0001193125-26-324866","cik":"0001314102","ticker":"EYPT","company_name":"EyePoint, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"eypt-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm"},"events":[{"id":22040,"run_id":19908,"accession_number":"0001193125-26-324866","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"EyePoint announced completion of enrollment in both pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema, with over 480 patients enrolled ahead of schedule in five months. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress toward potential regulatory approval and commercialization of its lead product candidate. The event is operational/strategic in nature—a major clinical program milestone—rather than fitting into financial, governance, legal, or terminal categories.","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21850,"accession_number":"0001193125-26-324866","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"EyePoint announced completion of enrollment in both pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema, with over 480 patients enrolled ahead of schedule in five months. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress toward potential regulatory approval and commercialization of its lead product candidate. The event is operational/strategic in nature—a major clinical program milestone—rather than fitting into financial, governance, legal, or terminal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:08:41.689595+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21850,"accession_number":"0001193125-26-324866","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"EyePoint announced completion of enrollment in both pivotal Phase 3 clinical trials (COMO and CAPRI) for DURAVYU in diabetic macular edema, with over 480 patients enrolled ahead of schedule in five months. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress toward potential regulatory approval and commercialization of its lead product candidate. The event is operational/strategic in nature—a major clinical program milestone—rather than fitting into financial, governance, legal, or terminal categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:08:41.689595+00:00","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-07-30"}]}